Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: Role in non–small cell lung cancer tumor proliferation  by Wald, Ori et al.
EVOLVING TECHNOLOGY/BASIC SCIENCEInteraction between neoplastic cells and cancer-associated fibroblasts
through the CXCL12/CXCR4 axis: Role in non–small cell lung cancer
tumor proliferationOri Wald, MD, PhD,a Uzi Izhar, MD,a Gail Amir, MD,b Sophie Kirshberg, BSc,c Zippora Shlomai, MSc,d
Gideon Zamir, MD,d Amnon Peled, PhD,c and Oz M. Shapira, MDaFrom th
stitut
Univ
Disclos
Read a
Surg
O.W. an
Receive
for pu
Address
dassa
mail.
0022-52
Copyrig
doi:10.1Objectives: Carcinoma-associated fibroblasts are reported to communicate microenvironment-derived signals
through chemokine/chemokine receptor interaction, influencing carcinogenesis. We sought to characterize roles
of CXCL12/CXCR4 in crosstalk between non–small cell lung cancer epithelial cell and carcinoma-associated
fibroblasts and in tumor growth.
Methods: Non–small cell lung cancer tumor samples obtained at surgery and from tumor arrays, as well as pri-
mary carcinoma-associated fibroblast and epithelial cell lines generated from fresh tumors, were assessed for
CXCL12/CXCR4 expression, tissue localization, and production. Colony assays, extracellular signal–regulated
kinase signaling, and chemokine production were measured to assess cancer cell responsiveness to CXCL12
stimulation with or without CXCR4 antagonists.
Results: CXCL12 and CXCR4 were detected in all major subtypes of non–small cell lung cancer. CXCL12-
expressing carcinoma-associated fibroblasts were mostly located near CXCL12-negative tumor cells, whereas
CXCL12-positive tumor cells were mostly surrounded by CXCL12-negative stroma. Intratumoral CXCL12
levels were significantly higher than serum levels. CXCL12 expression correlated with advanced disease stage.
In vitro, tumor cell lines produced variable amounts of CXCL12 and expressed high levels of CXCR4.
Carcinoma-associated fibroblasts cell lines produced high amounts of CXCL12 and expressed variable levels
of CXCR4. Stimulation of non–small cell lung cancer neoplastic cells with CXCL12 increased colony-
forming capacity, induced extracellular signal–regulated kinase phosphorylation, and production of the proin-
flammatory chemokine CCL20. CXCR4 antagonists attenuated these effects.
Conclusions: Interaction between carcinoma-associated fibroblasts and tumor epithelial cells through the
CXCL12/CXCR4 axis plays a role in non–small cell lung cancer tumor proliferation, marking this axis as a target
for immune intervention. (J Thorac Cardiovasc Surg 2011;141:1503-12)Neoplastic cells, carcinoma-associated fibroblasts (CAFs),
tumor-infiltrating immune cells, and vascular epithelial
cells are key components of the non–small cell lung cancer
(NSCLC) microenvironment. The interaction between tu-
mor cells and stromal cells is believed to influence
carcinogenesis. Previous studies have shown that NSCLC
tumors contain macrophages, immature dendritic cells,
and Foxp3 regulatory T cells infiltrate, suggesting that the
crosstalk among these cells and the neoplastic cells may en-
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SChemokines, a family of chemotactic cytokines, are mas-
ter regulators of immune cell trafficking in the body under
physiologic and pathologic conditions.4 Chemokines inter-
act with 7 transmembrane G-protein–coupled receptors to
exert their effects.4 Distinct immune cell subtypes express
specific repertoires of chemokine receptors, which guide
their trafficking, retention, and function in target organs.5
Avariety of tumor cells express chemokines and chemokine
receptors.6Activation of the chemokine/chemokine receptor
axis within tumors induces autocrine and paracrine loops,
promoting tumor growth and angiogenesis and subverting
antitumor immune response.6,7 For example, the
chemokine/chemokine receptor pair CXCL12/CXCR4 has
been shown to be a key mediator of tumor spread, site-
specific metastasis, and patient survival.6,8 Intense CXCR4
cytomembranous staining in NSCLC was associated with
distant metastasis and decreased disease-free survival in 2
human studies.9,10 In experimental models, expression of
CXCR4 by NSCLC cell lines was associated with
metastatic spread to organs highly expressing CXCL12.11
Multiple signaling pathway such as extracellular signal–
regulated kinase (ERK, p44/42 mitogen-activated proteindiovascular Surgery c Volume 141, Number 6 1503
Abbreviations and Acronyms
CAF ¼ carcinoma-associated fibroblast
ELISA ¼ enzyme-linked immunosorbent assay
ERK ¼ extracellular signal–regulated kinase
NSCLC ¼ non–small cell lung cancer
PCR ¼ polymerase chain reaction
RPMI ¼ Roswell Park Memorial Institute
medium
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Skinases), PI3 kinase, and neutral factor kB are activated
throughCXCL12/CXCR4 interaction. In nonmalignant cells,
ERK signaling cascades are involved in regulating cell prolif-
eration, survival, and differentiation.12 Chemokine/chemo-
kine receptor–mediated activation of ERK also plays a key
role in cancer cell proliferation and invasiveness.13-15
CXCR4 signaling though ERK has recently been shown to
promote pancreatic cancer cell proliferation and survival.16
In breast carcinoma, CAFs have been shown to promote
growth of mammary carcinoma cells and to enhance tumor
angiogenesis. This effect is in part mediated by
CXCL12.17,18 CAFs comprise a significant component of
NSCLC; however, their role in NSCLC pathogenesis has
not been well defined. Limited data are available on the
role of the CXCL12/CXCR4 axis and its signaling
pathway in NSCLC. We sought to characterize the roles
of the CXCL12/CXCR4 pair in the crosstalk between
NSCLC epithelial cell and CAFs and in tumor growth.MATERIALS AND METHODS
Tissue Collection and Patient-Specific Clinical Data
To exclude confounding effects, fresh tumor specimens, paraffin-
embedded tissue sections, and fresh blood samples were obtained from
patients (n ¼ 20) undergoing complete resection of early-stage NSCLC
(clinical stage IA–IIB) who had not undergone preoperative chemotherapy
or radiotherapy. Histologic sections were prepared from formalin-fixed,
paraffin-embedded tissues. Histopathologic diagnosis was confirmed by
an experienced pathologist (G.A.). To enlarge our tissue sample pool and
to allow clinical correlation, we also studied the expression of the
CXCL12/CXCR4 axis in 2 NSCLC arrays containing 59 and 99 samples,
respectively. Both arrays contained various subtypes of NSCLC.
The human component of the study was approved by the Hadassah
Hospital ethics committee, and the animal component was approved by
the animal experiment committee.
Immunohistochemistry of CXCL12 and CXCR4
NSCLC tissue samples were fixed with formalin and embedded in par-
affin. Antigen retrieval was performed in ethylenediaminetetraacetic acid
buffer for 20 minutes in a microwave, and sections were stained with the
monoclonal antibody 79018 (R&D Systems, Inc, Minneapolis, Minn) for
CXCL12 (1:100) and monoclonal antibody clone 12G5 (R&D Systems)
for CXCR4 (1:100) with a standard antimouse horseradish peroxidase
method according to the manufacturer’s instructions. For color develop-
ment, 3-amino-9-ethylcarbazole was used, and sections were counter-
stained with hematoxylin. Negative control sections were stained with1504 The Journal of Thoracic and Cardiovascular Sureither no primary antibody (phosphate-buffered saline solution) or with
isotype-matched control antibody.
Enzyme-Linked Immunosorbent Assays of CXCL12
and CCL20
Tumor tissue homogenates were prepared on ice from weighed tissue
samples. Plasma and NSCLC tissue homogenate CXCL12 levels, as well
as CCL20 levels in the supernatant collected from NSCLC cell lines,
were measured with enzyme-linked immunosorbent assays (ELISAs) per-
formed with a Quantikine kit (R&D Systems) according to the manufac-
turer’s instructions. Levels of CCL20 in the supernatant of the L4 cell
line in response to CXCL12 were measured in the presence or absence
of anti-CXCL12 antibody (10 mg/mL) and pertussis toxin (1 mg/mL).
Isolation of NSCLC Tumor Cells and CAFs
Fresh NSCLC tumor tissue samples were washed twice in 10 mL of
phosphate-buffered saline solution to remove remaining blood. Tissue was
cut into approximately 1-mm pieces and plated in Roswell Park Memorial
Institutemedium (RPMI) 1640 plus 10% fetal calf serum (Gibco; Invitrogen
Ltd, Paisley, UK). Tumor and fibroblast cells sprouting from the tumor ex-
plants were observed. We tried to generate primary culture tumor cells
and CAFs from 20 samples and succeed in selectively transferring and ex-
panding only 2 tumor cell and 4 fibroblast cell lines. To distinguish tumor-
derived neoplastic cells from tumor-derived fibroblasts, cells were initially
plated, stainedwith hematoxylin and eosin, and evaluated by an experienced
histopathologist (G.A.). Cells were then immunofluorescently stained for
cytokeratin and fibronectin. Tumor-derived neoplastic cells (L3 and L4)
were defined as cytokeratin positive and fibronectin negative. The L3 line
was generated from lung adenocarcinoma and theL4 line from large cell car-
cinoma. Tumor-derived fibroblasts (F1, F2, F3, and F4) were defined as
fibronectin positive and cytokeratin negative and generated from adenocar-
cinoma (F1, F3, and F4) and squamous cell carcinoma (F2) tumors.
In Vivo Experiments
A sample of 1.5 3 106 NSCLC-derived neoplastic cells (L3 and L4)
were injected into the tail veins of NOD-SCID mice. Two mice were in-
jected with each cell line. Ten weeks later, the mice were killed. The lungs
were fixed with formalin, embedded in paraffin, and assessed for tumor for-
mation by histologic and immunohistochemical methods.
Flow Cytometric Analysis of Neoplastic Cells and
CAFs
Weperformed flow cytometric analysis of 1.53 105 cells/mLof primary
tumor-derived neoplastic cells (L3 and L4), CAFs (F1, F2, F3, and F4), and
the NSCLC cell line A549 diluted in 0.1 mL phosphate-buffered saline so-
lution containing 0.1% bovine serum albumin (Biological Industries Israel
Beit-Haemek Ltd; Kibbutz Beit-Haemek, Israel) and 0.01% sodium azide
(fluorescence-activated cell sorting buffer). Nonspecific staining was
avoided by incubation with 1% human plasma for 15 minutes on ice.
Blocked cells were then mixed with phycoerythrin-conjugated anti-
CXCR4 monoclonal antibody (clone 12G5, 1:40; R&D Systems), with
polyclonal anti–CXCR4-N-terminus antibody (Chemicon International,
Temecula, Calif), or with isotype control for 20 minutes on ice and were
washed with fluorescence-activated cell sorting buffer. Immunostained
cells were analyzed by flow cytometry with the FACSCalibur Flow Cytom-
eter (BD Biosciences, Mountain View, Calif). For all analyses, gating was
performed using the forward scatter versus side scatter plot. Histogram
overlays of control and stained cells were generated. Data were analyzed
with the CellQuest software package (version 3.3; BD Biosciences).
Western Blot of ERK and Phosphorylated ERK
Western blot analysis for ERK and phosphorylated ERKwas carried out
as previously described in accordance with the manufacturer’sgery c June 2011
FIGURE 1. A, Expressions of CXCL12 and CXCR4 in non–small cell lung cancer tissue samples and plasma polymerase chain reaction assays for
CXCL12, CXCR4, and b-actin in 3 non–small cell lung cancer tumors. B, Enzyme-linked immunosorbent assay for CXCL12 concentration in fresh tumor
tissue and in the serum of patients operated on for non–small cell lung cancer; 4 cases are shown. C through H, Immunohistochemical staining for CXCL12.
C, Tumor-adjacent normal lung tissue. D, CXCL12-positive fibroblasts surrounding CXCL12-negative adenocarcinoma cells. E, CXCL12-positive fibro-
blasts and vascular structures surrounding CXCL12-negative adenocarcinoma cells. F, Both adenocarcinoma cells and tumor stroma staining positively for
CXCL12. G, CXCL12-positive fibroblasts and vascular structures surrounding CXCL12-negative squamous carcinoma cells. H, CXCL12-positive squa-
mous cell carcinoma. I, CXCR4-positive adenocarcinoma.
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and 10% fetal calf serum. After 24 hours, the medium was changed to
RPMI without fetal calf serum for an additional 24 hours. We then added
500 ng/mL of CXCL12 (R&D Systems). Cells were then harvested at 0,
5, 15, 30, and 60 minutes, and 0.1 mL of lysis buffer was added to each cul-
ture and incubated on ice for 5 minutes. Cell lysates were boiled for 5 min-
utes, and samples consisting of 60 mg protein were fractionated on 7% to
15% sodium dodecyl sulfate–polyacrylamide gel for 4 hours and trans-
ferred to nitrocellulose paper at room temperature overnight. The samples
were then incubated with the appropriate antibody (rabbit polyclonal
antibodies specific for ERK and phosphorylated ERK; Santa Cruz Biotech-
nology, Inc, Santa Cruz, Calif) according to the manufacturer’s recommen-
dations. Goat antirabbit horseradish peroxidase–conjugated antibody was
added for 30 minutes of incubation at room temperature. The nitrocellulose
blots were washed, enhanced chemiluminescence reagent was applied, and
autoradiography was developed on x-ray films in cassettes. The developed
bands were scanned and quantified with a densitometer ImageMaster VDS-
CL machine and the BIS 303 PC bioimaging systems (Pharmacia Biotech,
Piscataway, NJ).The Journal of Thoracic and CarColony Assays
Agar base layer was prepared as follows: 45 mL of RPMI plus12% fetal
calf serum was mixed with 15 mL of RPMI X2 plus 12% fetal calf serum
and with 15 mL of 2.5% agar in double distilled water. Tumor cells were
suspended in RPMI plus 10% fetal calf serum. Cell suspension was mixed
in a ratio of 1:3 with the agar base solution. This mixturewas then plated on
top of a preformed solid agar base. CXCL12was added to themixture at the
concentrations of 100 ng/mL and 500 ng/mL. Fourteen days later, the num-
bers of colonies were counted in 10 different fields. These experiments
were performed in the absence or presence of the CXCR4 inhibitor
AMD 3100 at a concentration of 10 mg/mL.Polymerase Chain Reaction
The following primers were used for polymerase chain reaction (PCR):
for CCL2, sense ATGAAAGTCTCTGCCGCCCT, antisense ACAG
ATCTCCTTGGCCACAA; for CXCR4, sense GCCTGAGTGCTCCAGT
AGCC, antisense GGAGTCATAGTCCCCTGAGC; for CXCL12, sense
ATGAACGCCAAGGTCGTGGTCG, antisense TGTTGTTGTTCTTCAdiovascular Surgery c Volume 141, Number 6 1505
FIGURE 2. Production of non–small cell lung cancer–derived neoplastic and carcinoma-associated fibroblast cell lines. Hematoxylin and eosin staining of
cancer epithelial cells (A) and cancer-derived fibroblasts (B). Cancer epithelial cells stained positively for cytokeratin (C) and negatively for fibronectin (E).
Carcinoma-associated fibroblasts were cytokeratin negative (D) and fibronectin positive (F).
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SGCCG; for CXCL8, sense TGCCAAGGAGTGCTAAAG, antisense
TCTCAGCCCTCTTCAAAA; and for vascular endothelial growth factor,
sense ACATTGTTGGAAGAAGCTGC, antisense ATCCTGCCCTGTCT
CTCTGT.
Statistical Analysis
Data are expressed as mean  SE and as absolute values with percent-
ages. Continuous data with normal distribution were analyzed with the t
test. Categoric data were analyzed with the Mann–Whitney U test. Statis-
tical analyses were performed with the SPSS statistical software package
(SPSS, an IBM Company, Chicago, Ill).
RESULTS
To assess the potential role of the CXCL12 /CXCR4 axis
in NSCLC cancer, we examined fresh tumor tissues ob-
tained from our patients during surgery, plasma obtained
from these patients, and NSCLC tumor arrays, as well as
cell lines we generated from NSCLC tumors.
Expression of CXCL12/CXCR4 in NSCLC Tissue
Samples and Plasma
The expressions of CXCL12 and CXCR4 in fresh
NSCLC samples were assessed by PCR. Figure 1, A, depicts1506 The Journal of Thoracic and Cardiovascular Sur3 representative patients, documenting expressions of the li-
gand and its receptor.
In immunohistochemical analysis, we found distinct pat-
terns of CXCL12 expression by NSCLC neoplastic cells
and CAFs. Tumor-adjacent normal lung epithelial cells
stained negative for CXCL12 (Figure 1, C). CXCL12-
positive fibroblasts surrounded CXCL12-negative tumor
tissue (Figure 1,D, adenocarcinoma, Figure 1,G, squamous
cell carcinoma). CXCL12 was also expressed in small ves-
sels and stroma adjacent to CXCL12-negative neoplastic
cells (Figure 1, E, adenocarcinoma). In some cases,
neoplastic cells expressed high levels of CXCL12 and stro-
mal cells were negative (Figure 1, H, squamous cell carci-
noma). Finally, we observed a pattern of CXCL12
expression by both neoplastic and stromal cells (Figure 1,
F, adenocarcinoma).
Both neoplastic cells and CAFs produced CXCL12.
CXCL12-expressing CAFs and stroma were mostly de-
tected in proximity to CXCL12-negative tumor tissues.
CXCL12-positive tumor cells were mostly surrounded by
CXCL12-negative stroma.gery c June 2011
FIGURE 3. Characterization of non–small cell lung cancer–derived neoplastic cell lines. A, Polymerase chain reaction results for CXCL12, CXCR4, and
b-actin in the cancer epithelial cell lines L3, L4, and A549. B, ELISA assay for CXCL12 secretion to the medium at 24, 48, and 72 hours after plating of L3,
L4, and A549 cells. C, Flow cytometric analysis of CXCR4 expressions by L3, L4, and A549. Representative forward and side scatter dot plot and cell gating
of L3 is shown at right. Histogram of control antibody and overlay with anti CXCR4 antibody for L3, L4, and A549 are shown at left. Representative he-
matoxylin and eosin (D and E) and cytokeratin (F) staining of L4-derived tumors forming in the lungs of NOD-SCIDmice after injection of the cells into the
tail vein. SSC, Side scatter; FSC, forward scatter; PE, phycoerythrin.
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expression in NSCLC tumors (Figure 3, I, adenocarci-
noma).
CXCL12 levels within NSCLC tumors were significantly
higher than the serum levels of the protein (Figure 2, B).
CXCL12 Expression and NSCLC Pathologic Stage
Expression of CXCL12 was detected in all major sub-
types of NSCLC: adenocarcinoma, squamous cell carci-
noma, bronchoalveolar carcinoma, and large cell
carcinoma. Among the 59 samples in the first array, 48 sam-
ples(81%) stained positively for CXCL12 and 11 (19%)
stained negatively. The proportions of CXCL12-positive
samples according to disease stage were 23 of 31 (74%)
for stage I, 15 of 17 (88%) for stage II, 9 of 10 (90%) for
stage III, and 1 of 1 (100%) for stage IV (P¼ .145). Nearly
all samples in the second array stained positively for
CXCL12 in variable intensity. We classified the tumor
samples as having high or low CXCL12 expression. High
expression of CXCL12 was noted if more than 50% of
neoplastic cells stained positively for CXCL12. TheThe Journal of Thoracic and Carproportions of tumors with high CXCL12 expression ac-
cording to disease stage were 17 of 44 (39%) for stage I,
11 of 23 (48%) for stage II, 19 of 31 (61%) for stage III,
and 1 of 1 (100%) for stage IV (P ¼ .043). Thus
CXCL12 expression appears to correlate with a more
advanced disease stage.
Production and Characterization of NSCLC-Derived
Neoplastic and CAF cell lines
Four primary cell cultures of CAFs (F1, F2, F3, and F4)
and 2 of NSCLC neoplastic cells (L3 and L4) were gener-
ated from fresh tissue samples of NSCLC tumors removed
during surgery. Representative staining of these cells with
hematoxylin and eosin is shown in Figure 2 (Figure 2, A
and B). Cells were further characterized with immunohisto-
chemistry. NSCLC neoplastic cells stained positively for
cytokeratin and negatively for fibronectin (Figure 2, C
and E). In contrast, CAFs stained negatively for cytokeratin
and positively for fibronectin (Figure 2, D and F).
PCR analysis of NSCLC-derived neoplastic cell lines L3
and L4 and the established NSCLC cell line A549 showeddiovascular Surgery c Volume 141, Number 6 1507
FIGURE 4. Characterization of non–small cell lung cancer–derived carcinoma-associated fibroblast cell lines. A, Polymerase chain reaction results for
CXCL8, CXCL12, CCL2, and b-actin in 2 carcinoma-associated cell lines, F1 and F2. B, Enzyme-linked immunosorbent assay results for CXCL12 secre-
tion to the medium at 24, 48, and 72 hours after plating of F1 and F2 cells. C, Immunohistochemical staining for CXCR4; black arrows point to CXCR4-
positive fibroblast. D, Flow cytometric analysis of CXCR4 expression by carcinoma-associated fibroblast cell lines F1, F2, and F3. Histogram of control
antibody and overlay with anti-CXCR4 antibody for F1, F2, and F3 are shown. PE, Phycoerythrin.
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Sdifferential expression of CXCL12 (Figure 3, A). L3 cells
showed a strong PCR signal for CXCL12. Production of
CXCL12 by L3 cells was time dependent, reaching high
levels of the chemokine after 72 hours (Figure 3, B). In con-
trast, L4 and A549 cell lines showed low PCR signal and re-
duced secretion of the chemokine (Figure 3, A and B). PCR
signal for CXCR4 was detected in all neoplastic cells
(Figure 3, A), and high membranous expression was de-
tected by flow cytometry (Figure 3, C).
To demonstrate the tumorigenic potential of these cells,
L3 and L4 neoplastic cells were injected into NOD-SCID
mice, and the lungs were histologically assessed as de-
scribed in the Methods section. All mice showed develop-
ment of tumors. Figure 3 (D, magnification 34, and E,
magnification 320) shows representative sections from
these mice with tumor foci in the lungs, staining positive
for cytokeratin (Figure 3, F).
By PCR analysis, we found all 4 CAF cell lines to ex-
press an array of tumor-promoting chemokines. Figure 4,1508 The Journal of Thoracic and Cardiovascular SurA, demonstrates the expressions of CXCL8, CXCL12,
and CCL2 in F1 and F2 CAF lines. With ELISA, we
showed that CAFs in culture produce CXCL12 in a time-
dependent fashion similar to that of L3 neoplastic cells
(Figure 4, B).
Staining of NSCLC tissue sections for CXCR4 indicated
that some of the tumor fibroblasts expressed CXCR4
(Figure 4, C). Flow cytometry confirmed differential
expression of CXCR4 by 3 CAF lines (Figure 4D).
CXCL12 Induces NSCLC Proliferation, ERK
Phosphorylation, and CCL20 Production
The effects of CXCL12 stimulation on neoplastic cell
proliferation were studied with colony assays. Stimulation
of L3, L4, and A549 cells by increasing concentrations of
CXCL12 promoted colony formation in a dose-dependent
fashion (Figure 5, A, B, and C). CXCL12-induced colony
formation could be blocked by the CXCR4-specific inhibi-
tor AMD3100 (Figure 5, D, E, and F).gery c June 2011
FIGURE 5. CXCL12-induced non–small cell lung cancer proliferation, extracellular signal–regulated kinase phosphorylation, and CCL20 production. A
to C, Colony formation by L3, L4, and A549 cells in response to increasing concentration of CXCL12. D to F, Colony formation by L3, L4, and A549 cells in
response to increasing concentration of CXCL12 with and without the addition of the CXCR4 antagonist AMD3100. G to I, Western blot analysis for phos-
phorylated extracellular signal–regulated kinase (Perk, upper panel) and extracellular signal–regulated kinase (erk, lower panel) after stimulation of L3, L4,
and A549 cells with CXCL12. J to L, Enzyme-linked immunosorbent assay results for CCL20 secretion after stimulation with increasing concentrations of
CXCL12 for L3, L4, and A549 cell lines. M, Enzyme-linked immunosorbent assay results for CCL20 secretion after CXCL12 stimulation with and with out
the addition of anti-CXCR4 antibodies or pertussis toxin for L4 cell line. Asterisk indicates P<.05; double asterisk indicates P<.01.
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SCXCL12 stimulation of L3, L4, and A549 cells induced
ERK phosphorylation 15 and 30 minutes after exposure
(Figure 5,G, H, and I, upper panel). There were no changes
in total ERK levels (lower panel).
Finally, we found that stimulation of all 3 neoplastic cell
lines by CXCL12 induced the secretion of the proinflamma-
tory chemokine CCL20 (Figure 5, J, K, and L). The effects
were more pronounced in the L4 and A549 lines. Pertussis
toxin and anti-CXCR4 antibodies abrogated CXCL12-
induced CCL20 secretion in L4 cells (Figure 5, M).
DISCUSSION
Previous studies have shown that all major subtypes of
NSCLC tumors express CXCR4.9-11,20,21 CXCR4
expression has been detected in the nucleus, the
cytomembranous compartment, or both.9-11, 20-22 Su and
colleagues6 have reported that high cytomembranous
CXCR4–expressing tumors were more prone to metastasis
than were low CXCR4–expressing tumors. Spano and asso-
ciates21 have reported that strong CXCR4-positive nuclear
staining was associated with improved outcomes in early-
stage NSCLC. Wagner and colleagues10 have confirmed
these findings and suggested that cytomembranous expres-
sion of the CXCR4 in lung adenocarcinoma is an indepen-
dent risk factor for decreased disease-free survival, whereas
nuclear staining confers a survival benefit. These clinical
studies indicate cytomembranous expression of CXCR4 in
NSCLC as a prognostic marker.
The prognosis of patients with NSCLC is related to tumor
metastasis. The primary sites of lung cancer metastasis,
such as bone, liver, adrenal glands, and brain, express
high levels of CXCL12.23 Thus CXCR4 may a play an im-
portant role in guiding NSCLC sites of metastasis. Phillips
and coworkers11 showed that administration of anti-
CXCL12 neutralizing antibodies to immunodeficient mice
with human NSCLC abrogated organ metastasis. Economi-
dou and associates20 suggest that high CXCL12 levels in
pleural effusion of patients with NSCLC may be associated
with tumor seeding of pleural space.
In this study, we showed that more than 80% of NSCLC
expressed CXCL12. Intratumoral levels of the protein were
much higher than in peripheral blood. Thus CXCR4-
mediated metastatic spread of NSCLC may not be solely
explained by migration of tumor cells into CXCL12-
expressing tissues. The local concentration of CXCL12
and the expression of CXCR4 by neoplastic cells in the
microenvironment seem to be of critical importance.24
Taken together, our data suggest that CXCL12/CXCR4
interactions occur in the tumor microenvironment and
may act locally to support tumor growth.
With immunohistochemical staining, we observed
CXCL12 expression by both CAFs and neoplastic cells. All
primary CAF cell lines produced CXCL12 in vitro. In con-
trast, the production of this chemokinebyneoplastic cell lines1510 The Journal of Thoracic and Cardiovascular Surwas variable. The neoplastic cell lines consistently expressed
high levels of CXCR4. This led us to examine the effects of
CXCL12 stimulation on the neoplastic cell lines. We found
that CXCL12 promoted the colony-forming capacity of
NSCLC cells, an effect that was inhibited by the CXCR4 an-
tagonist AMD3100. Thus CXCL12 may act locally to sup-
port tumor cell growth in either an autocrine or paracrine
manner. The detection of CXCL12-expressing CAFs in the
tumormicroenvironment is intriguing. It is possible that these
cells participate in the process of neoangiogenesis. Orimo
and colleagues17 described such a mechanism for tumor
propagation in a model of breast carcinoma.
We have previously reported that the prognosis of pa-
tients with NSCLC might be related to tumor CXCL12
levels.3 Recurrence rates were higher (7/21) among patients
with intense CXCL12 staining than among those who had
weak staining (0/8).3 This study supports that observation
by showing a correlation between the pathologic disease
stage and CXCL12 levels. These findings are also in accor-
dance with other studies showing a linkage of advanced T
score, lymph node metastasis, and high tumoral CXCL12
levels. Lymph node metastasis has also been linked to
strong nuclear CXCR4 staining.22 These data suggest that
CXCR4 might not be the sole mediator guiding trafficking
of tumor cells into lymph nodes. Other chemokines, such as
CCL21 and CCL19, may participate in the process and have
been shown to regulate CCR7-dependent T-cell and den-
dritic cell trafficking into lymph nodes.4 Takanami25
showed that 57.8% of patients with positive tumoral
CCR7 messenger RNA expression had lymph node metas-
tasis, whereas only 11.5% of those without CCR7 messen-
ger RNA expression had lymph involvement. Overall, these
clinical and experimental data suggest that the CXCL12/
CXCR4 signaling pathway promotes tumor cell prolifera-
tion. Trafficking of cancerous cells into draining lymph no-
des may depend on other chemokines and receptors. Once
in the lymph node, CXCL12/CXCR4 autosignaling may
augment metastasis growth.
The mechanisms and signaling pathways involved in
CXCL12/ CXCR4 activation in NSCLC have not been fully
identified. A recent report by Lee and coworkers26 marks
ERK activation as a key pathway in NSCLC development.
In this study, we found that CXCL12 induced ERK
phosphorylation in all neoplastic cell lines tested. ERK
phosphorylation is a common pathway of extracellular-
stimulated signaling cascades involved in the regulation
of tumor cell proliferation and cytoskeletal rearrange-
ment.12,27 CXCL12-induced ERK phosphorylation has
been shown to induce matrix metalloproteinase 9 secretion
and to augment the motility of NSCLC tumor cells.13,28 We
found that CXCL12-expressing CAFs and stroma were
mainly detected in proximity to CXCL12-negative tumor
tissues. It is therefore possible that such sites represent tu-
mor niches that facilitate tumor cell detachment and releasegery c June 2011
Wald et al Evolving Technology/Basic Scienceto the circulation. Furthermore, distant sites where CXCL12
is highly expressed may serve as favorable niches for metas-
tasis to occur. At these locations, a paracrine CXCL12/
CXCR4 loop may stimulate tumor cell proliferation and
induce extracellular matrix rearrangement, necessary for
metastasis formation.
Finally, we showed that CXCL12 stimulation resulted in
production of the proinflammatory chemokine CCL20 by
neoplastic cells. This may explain our previous observation
that CXCL12 expression in lung adenocarcinoma was asso-
ciated with increased tumor inflammatory load and the ac-
cumulation and retention of CD4þ T cells.3 In addition to
CD4þT cells, immature dendritic cells were also shown to
accumulate in NSCLC.2 The trafficking of such cells is gov-
erned in part by both CXCL12 and CCL20.2,5 Dumitriu and
colleagues29 recently described the potential of dendritic
cells to induce differentiation of FoxP3 regulatory T cells
on exposure to NSCLC cells.29 Thus augmentation of tumor
inflammation and recruitment of tumor promoting rather
than suppression of immune cells may be an additional
mechanism by which the CXCL12/CXCR4 axis promotes
NSCLC growth and spread.
In conclusion, our findings suggest that the interaction of
CAFs and tumor neoplastic cells and the CXCL12/CXCR4
axis play a role in tumor cell proliferation, thus marking
CXCL12/CXCR4 axis as a target for immune intervention
in the treatment of NSCLC.E
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Dr Steven J. Mentzer (Boston, Mass). Thank you, Dr Wald.
That was a nice presentation, and your written article was equally
thoughtfully put together.
For those of us who sometimes blur when we think about chemo-
kines—and I think there are now roughly 44 or 45 chemokines
known, so I think often people tune out—there are a few that are
very important to thoracic surgeons. CCL2, or the old MCP-1,
seems to be involved in a lot of different lung diseases, and
CXCR4 is very important in terms of human cancer. I think it has
been demonstrated in more than 20 human cancers. One of the
things that I think is interesting about your study is the heterogeneitydiovascular Surgery c Volume 141, Number 6 1511
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Sin the samples that you showed, at least in the written article. Did
you look at metastatic disease? If you imagine a subpopulation
and if, for example, CXCR4 expression were important, you would
perhaps expect that to be selected for in metastatic disease. Did you
have an opportunity to look at that in any metastatic lesions?
Dr Wald. Well, we have conducted 2 studies focusing mainly
on CXCL12, because some data regarding the expression of
CXCR4 had already been published. In 2 different series, 1 that
we reported in the past and 1 that we have now, we found some cor-
relation between the level of CXCL12 expression and recurrence
of disease. I assume that the balance of expression between the
chemokine and the receptor will determine the outcome in many
patterns. If you have expression of both the chemokine and the re-
ceptor in the tumor microenvironment, you might think that an au-
tocrine loop or a paracrine loop is actually acting and may support
tumor growth locally, whereas if you have, for example, expres-
sion of the chemokine on vascular structures and fibroblasts at
the tumor edge or border with expression of the chemokine itself
by the tumor cells, then this pattern might favor the possibility
of guiding tumor metastatic spread. I think, however, that this is
something that would be difficult to prove.
Dr Mentzer. One of the problems with a lot of chemokine re-
search is that people kind of reach too far. They try to overinterpret
their data. The CXCL12, it’s actually stromal cell–derived factor 1
(SDF-1); it stops lymphocytes on a dime, it recruits endothelial
progenitor cells, and it is expressed in a lot of tumors. It does
a lot of different things. I don’t think you have to try to explain
it in in vitro work. And particularly the problem with in vitro
work is that the cells are responding to polystyrene, not to the tu-
mor microenvironment, which I think is a practical problem.
I think back to 8 or 10 years ago, when this was first discov-
ered in breast cancer metastatic disease, Dynex and a variety of1512 The Journal of Thoracic and Cardiovascular Surother companies were developing small-molecule inhibitors.
Can you envisage that kind of therapeutic potential in treating
lung cancer?
Dr Wald. Well, today there is 1 molecule that is already ap-
proved for clinical use, I think it is AMD3100 (Plerixafor). I think
that the method of delivery is highly important, because, as you
mentioned, the CXCL12/CXCR4 axis is important in many ho-
meostatic processes in the body. So if one wants to look at this
as a therapeutic target, one must look for a way to deliver the
drug specifically into the tumor, or at least use molecules that
have a short half-life, maybe that predispose the cells to the action
of other therapeutic agents, such as chemotherapy. I think this
might be the path.
Dr Mentzer. Nice work. Thank you.
Dr Nasser K. Altorki (New York, NY). I want to congratulate
you on pursuing this idea of crosstalk between the CAFs and the
tumor. This will be an area of great interest going forward.
I understood you to say that thesewere primary-derived cultures
from tumors, and I wondered whether you could share with us
some of the tricks that you used to develop epithelial cell lines, be-
cause in our hands the success rate is less than 10%.
Dr Wald. I’m afraid, as we wrote in the article, that our per-
centage of success is around 10%. I think that it’s very tough to
isolate the primary tumor cells. I know that other people in our
institution have tried to collect them from pleural effusions, and
they have a had a relatively high rate of success. What we have
done, and sometimes it seems promising, is initially grow the
cells on plates and then use like a colony assay and select specific
colonies. There are also kits available for that, which seemed to
be a bit more useful in some of the cases, but the success rate
is still low.
Dr Altorki. Thank you, and congratulations.gery c June 2011
